# What Your Doctor Cannot See

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/what-your-doctor-cannot-see

> Compounded semaglutide and tirzepatide appear in 8.2% of primary care records. Surveys put real use near 23%, so most of it is invisible to the record and to everything that depends on it.

## Key points

- 8.2% documented in records vs ~23% by patient survey, so most compounded use is invisible.
- Brand prescriptions are structured data; compounded use had to be dug out of clinical notes.
- Interaction checking, pre-procedure planning and safety surveillance all run off the record.
- Compounded users skewed WEALTHIER, White, female and non-diabetic, the opposite of the usual framing.
- Deprivation was measured by area, not individual income.
- Compounded-only users stayed on longer: 10.0 vs 7.8 months.

Compounded semaglutide and tirzepatide appear in **8.2%** of primary care records for people taking these drugs. Surveys of patients put the real figure near 23%.[1] If both are right, roughly two-thirds of compounded use is invisible to the medical record, and everything that depends on the record fails quietly along with it.

## Why the gap exists

Researchers examined a nationwide database of primary care records covering 153,044 patients with documented semaglutide or tirzepatide use between 2021 and 2024. Brand-name prescriptions were straightforward to find, because they sit in structured prescribing data.

Compounded use had to be extracted from **clinical notes**. There is no prescription record in the system, because the drug did not come through it. It exists in the chart only if the patient mentioned it and a clinician typed it out.

> A medication bought outside the system leaves no trace inside it unless someone writes one.

## What stops working

> **The record is not paperwork. It is the input to several systems that protect you.** Automated interaction checking runs against the medication list. Pre-procedure planning depends on knowing what someone takes, and these drugs specifically change how a stomach empties before anesthesia. Adverse events get attributed to the drugs a chart says you are on. National safety surveillance aggregates exactly this data.

- **Drug interactions.** These medicines slow gastric emptying, which affects how other oral drugs are absorbed (covered in [your other medications](https://glpwatchdog.org/research/glp1-and-your-other-medications)). A checker cannot flag a drug it does not know about.
- **Surgery and endoscopy.** The odds of retained stomach contents despite fasting are roughly six times higher on these drugs,[2] which changes how a procedure is prepared for (see [before endoscopy and surgery](https://glpwatchdog.org/research/glp1-before-endoscopy-and-surgery)).
- **Side-effect attribution.** A symptom is far less likely to be connected to a medication nobody has recorded.
- **Safety surveillance.** If two-thirds of compounded use is invisible, so is two-thirds of whatever it causes.

None of that requires anyone to have done anything wrong. It follows from a supply route that runs around the system rather than through it.

## Who is using it

> **Compounded users were more likely to live in areas of *lower* socioeconomic deprivation (that is, wealthier areas), and more likely to be female, non-Hispanic White, and non-diabetic.** Compounded product is routinely described as the affordable option for people priced out of the brand. In this dataset it looks more like cash-pay weight treatment among people with money to spend on it.

The non-diabetic part fits that reading. Someone with type 2 diabetes has a covered indication and a prescriber writing brand-name product; someone seeking weight treatment without a covered indication is paying either way, and a cheaper cash price is a smaller obstacle than an insurance denial.

One caution on how far to take this. Socioeconomic deprivation here is measured by *area*, not by individual income. It is a neighborhood-level proxy that describes where someone lives rather than what they earn: a real signal, but a blunt one.

The study also found compounded-only users stayed on treatment longer, averaging 10.0 months against 7.8 for brand-only users. We are not going to explain that confidently. It could be uninterrupted cash-pay supply against insurance that lapses, or a difference in who chooses which route, or something the data cannot see.

## What follows from it

The actionable part is short. If you are taking a compounded GLP-1, the single most useful thing you can do is make sure it is **written in your chart**, with the drug, the dose, and who supplies it.

- **Tell any clinician, including ones you see for something unrelated.** The connection is not obvious and they will not ask.
- **Tell anyone scheduling a procedure**, early enough that it can change the plan.
- **Ask for it to be added to your medication list**, not just mentioned. A note in prose does not reach the interaction checker.
- **Keep the supplier’s details**, because if something goes wrong the pharmacy of record matters (see [verify what you received](https://glpwatchdog.org/research/verify-the-glp1-you-received)).

That last detail is easier to hand over when the seller publishes it. [Elara MD](https://glpwatchdog.org/reviews/elara-md), [Neo Soma Healthcare](https://glpwatchdog.org/reviews/neo-soma-healthcare) and [Contour Health](https://glpwatchdog.org/reviews/contour-health) each name Strive Pharmacy as the pharmacy that fills their prescriptions. [Next Vial](https://glpwatchdog.org/reviews/next-vial) and [Candor Rx](https://glpwatchdog.org/reviews/candor-rx) name Manifest Pharmacy in Greer, South Carolina.

A few name pharmacies outside that pair. [Cora Health](https://glpwatchdog.org/reviews/cora-health) lists Hallandale Pharmacy and VialsRx, [Fierce Health](https://glpwatchdog.org/reviews/fierce-health) names Red Rock Pharmacy in Utah, and [ShapeIn Rx](https://glpwatchdog.org/reviews/shapein-rx) names Compounding Pharmacy of America. [MEDVi](https://glpwatchdog.org/reviews/medvi) and [ElixaMD](https://glpwatchdog.org/reviews/elixamd) both name [Triad Rx](https://glpwatchdog.org/pharmacies/triad-rx), RedRock Pharmacy and Beaker Pharmacy & Compounding. Where a seller lists more than one pharmacy, the label on the vial in your hand is what tells you which one to write down.

[Kora MD](https://glpwatchdog.org/reviews/kora-md) lists four: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx. [Zevay](https://glpwatchdog.org/reviews/zevay) names Southend Pharmacy and Boothwyn Pharmacy, and Boothwyn received an FDA warning letter in January 2026, one more reason to know which of the two filled your order.

The study covers 2021 to 2024, a period defined by shortages that have since closed. Whether the documentation gap has narrowed as the legal basis for compounding changed is not something this data answers. The shifting rules are in [which GLP-1s can be compounded](https://glpwatchdog.org/research/which-glp1-can-be-compounded).

## Frequently asked questions

### How many people use compounded GLP-1 drugs?

Documentation in US primary care records put it at 8.2% of patients on these medications between 2021 and 2024. Patient surveys have reported around 23%, which suggests most compounded use is not reaching the medical record.

### Why would it not be in my record?

Brand-name prescriptions appear in structured prescribing data automatically. Compounded product bought outside that route leaves no entry, so it exists in the chart only if you mention it and a clinician writes it down.

### Does that matter?

Yes. Automated interaction checking, pre-procedure planning, side-effect attribution and national safety surveillance all run off the medication record. A drug that is not listed is invisible to all of them.

### Are compounded users people who cannot afford the brand?

Not in this dataset. Compounded users were more likely to live in wealthier areas and to be non-diabetic, which looks more like cash-pay weight treatment than a budget substitute. Deprivation here is measured by area rather than individual income, so it is a blunt signal.

### What should I do?

Make sure it is written in your chart as a medication rather than mentioned in passing, tell any clinician you see including for unrelated problems, and tell anyone scheduling a procedure early enough for it to change the plan.

## References

1. Hendrix N, Velásquez EE, Pham H, Bazemore A. Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. Pharmacoepidemiology and Drug Safety. 2025. PMID: 41024632. https://pubmed.ncbi.nlm.nih.gov/41024632/
2. Elkin J, Rele S, Sumithran P, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. Anaesthesia. 2025. PMID: 40230298. https://pubmed.ncbi.nlm.nih.gov/40230298/

---

Cite as: GLP Watchdog, Nora Bissett, "What Your Doctor Cannot See", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/what-your-doctor-cannot-see

Canonical HTML page: https://glpwatchdog.org/research/what-your-doctor-cannot-see

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
